Momenta Sues Teva to Block Proposed Lovenox Rival

Momenta Pharmaceuticals Inc., which receives royalties from the only approved generic version of the blood thinner Lovenox, filed a patent-infringement suit to block a potential rival drug from Teva Pharmaceutical Industries Ltd.

Momenta and its partner, Novartis AG’s Sandoz, began selling copies of the Sanofi-Aventis SA drug after receiving U.S. Food and Drug Administration approval July 23. In November, Teva, the world’s biggest generic-drug maker, told investors that its proposed generic copy met the FDA’s standard for chemical sameness and it was making progress toward approval.